Storia in 1 fonti

AbbVie receives EC approval for Aquipta to treat migraine

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Raccontata da

pharmaceutical-technology.com

Timeline cronologica

mercoledì 3 giugno 2026·pharmaceutical-technology.com
AbbVie receives EC approval for Aquipta to treat migraine
AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.